<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor VIIa (activated), recombinant human: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor VIIa (activated), recombinant human: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor VIIa (activated), recombinant human: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10155" href="/d/html/10155.html" rel="external">see "Factor VIIa (activated), recombinant human: Drug information"</a> and <a class="drug drug_patient" data-topicid="11536" href="/d/html/11536.html" rel="external">see "Factor VIIa (activated), recombinant human: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F10053630"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Thrombosis: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive Factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis. </p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169443"><span class="drugH1">Brand Names: US</span>
<ul>
<li>NovoSeven RT;</li>
<li>Sevenfact</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866857"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>NiaStase RT</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058582"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462445"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2f4f0b3-4b98-4bc1-a849-49291ef24c40">Hemophilia A or B with inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A or B (congenital) with inhibitors: </b>
<b>Note: </b>Dose, frequency, and duration of therapy should be individualized based on severity of the bleeding, need for urgent hemostasis, and prior patient response to factor VIIa bypassing agents in previous bleeding events.</p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> IV: 90 mcg/kg/dose every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35 to 90 mcg/kg have been used successfully in clinical trials. The dose, frequency, and duration of therapy may be adjusted based on severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds to maintain the hemostatic plug, dosing should be continued at 3- to 6-hour intervals; the duration of post-hemostatic dosing has not been studied. Monitor and minimize the duration of post-hemostatic dosing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> IV: 90 mcg/kg immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 48 hours, then every 2 to 6 hours until healing is achieved. For major surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 5 days, then every 4 hours or by continuous infusion at 50 mcg/kg/hour until healing achieved.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c1e5e49-ca8e-4707-bbc0-ed7af4ce60d7">Congenital factor VII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital factor VII deficiency:</b> NovoSeven RT: <b>Note: </b>Dose and frequency should be individualized for each patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bleeding episodes:</i> IV: 15 to 30 mcg/kg/dose every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perioperative management:</i> IV: 15 to 30 mcg/kg immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg have been effective.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9763a7a-dfcc-491c-9885-ebb564d91513">Glanzmann thrombasthenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glanzmann thrombasthenia:</b> NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bleeding episodes, severe (refractory to platelet transfusions):</i> IV: 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perioperative management:</i> IV: 90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher doses (100 to 140 mcg/kg) can be used for surgical patients who have clinical refractoriness with or without platelet-specific antibodies.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F169454"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2f4f0b3-4b98-4bc1-a849-49291ef24c40">Hemophilia A or B with inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A or B (congenital) with inhibitors: Note:</b> Dose, frequency and duration of therapy should be individualized based on severity of the bleeding, need for urgent hemostasis, and prior patient response to factor VIIa bypassing agents in previous bleeding events.</p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> Infants, Children, and Adolescents: IV: 90 mcg/kg/dose every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35 to 90 mcg/kg have been used successfully in clinical trials. The dose, frequency, and duration of therapy should be adjusted based on severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds to maintain the hemostatic plug, dosing should be continued at 3- to 6-hour intervals; the duration of post-hemostatic dosing has not been studied. Monitor and minimize the duration of post-hemostatic dosing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> Infants, Children, and Adolescents: IV: 90 mcg/kg immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg/dose every 2 hours for 48 hours, then every 2 to 6 hours until healing achieved. For major surgery, continue 90 mcg/kg/dose every 2 hours for 5 days, then every 4 hours or by continuous infusion at 50 mcg/kg/hour until healing achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Secondary prophylaxis of bleeding events:</i> Very limited data available: Children ≥5 years and Adolescents: IV: 90 mcg/kg/dose <b>OR </b>270 mcg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17723130','lexi-content-ref-27913543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17723130','lexi-content-ref-27913543'])">Ref</a></span>). Dosing based on a trial which enrolled 22 male patients, including 16 pediatric patients (age: 5 to &lt;18 years), with severe congenital hemophilia with high inhibitor titers, a need for treatment with bypassing agents, and who had experienced at least 4 bleeds requiring hemostatic therapy the previous month. Patients were randomized to receive either 90 mcg/kg/dose or 270 mcg/kg/dose IV daily as prophylaxis for 3 months. The overall bleeding frequency was reduced by 45% and 59% in the 90 mcg/kg group and the 270 mcg/kg group, respectively, with the most significant decrease was seen in joint bleeds. No thromboembolic events were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17723130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17723130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SevenFact: <b>Note: </b>Maximum dosage has not been established; cumulative daily dosages &gt;900 mcg/kg, which may be associated with a greater risk of thromboembolic complications, have not been studied. The dose, frequency, and duration of therapy should be adjusted based on patient's response to therapy and the degree of hemostasis achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild to moderate bleeding (eg, joint, superficial muscle, soft tissue and mucous membranes)</i>: IV: 75 mcg/kg/dose every 3 hours until hemostasis is achieved <b>OR</b> initial dose of 225 mcg/kg and if hemostasis is not achieved within 9 hours, administer 75 mcg/kg/dose every 3 hours as needed to achieve hemostasis. If successful control of bleeding does not occur within 24 hours of initial administration, consider alternative treatments. Continue therapy to support healing and prevent recurrent hemorrhage after hemostasis to maintain the hemostatic plug. Duration of therapy should be individualized by site and severity of bleeding.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe bleeding (eg, life- or limb-threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or GI)</i>: IV: Initial: 225 mcg/kg/dose, then 6 hours later (if needed) administer 75 mcg/kg/dose every 2 hours until hemostasis is achieved; continue therapy to support healing and prevent recurrent hemorrhage. Duration of therapy should be individualized based on site and severity of bleeding and use of other procoagulant therapies. Consider the risk of thrombosis with subsequent dosing after hemostasis achieved.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c1e5e49-ca8e-4707-bbc0-ed7af4ce60d7">Congenital factor VII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital factor VII deficiency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT: Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> 15 to 30 mcg/kg/dose every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg/dose have been effective. Adjust dose and frequency to each individual patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 15 to 30 mcg/kg immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg/dose have been effective. Adjust dose and frequency to each individual patient.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9763a7a-dfcc-491c-9885-ebb564d91513">Glanzmann thrombasthenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glanzmann thrombasthenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT: Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes, severe (refractory to platelet transfusions):</i> 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 90 mcg/kg immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher doses of 100 to 140 mcg/kg can be used for surgical patients who have clinical refractoriness with or without platelet-specific antibodies.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109813"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51109814"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F169445"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10155" href="/d/html/10155.html" rel="external">see "Factor VIIa (activated), recombinant human: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfdc10e-2685-4912-8991-cd2aaef9ef0b">Acquired hemophilia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acquired hemophilia: </b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> 70 to 90 mcg/kg/dose every 2 to 3 hours until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 70 to 90 mcg/kg/dose immediately before surgery; repeat every 2 to 3 hours for the duration of surgery and until hemostasis achieved.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c1e5e49-ca8e-4707-bbc0-ed7af4ce60d7">Congenital factor VII deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital factor VII deficiency: </b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> 15 to 30 mcg/kg/dose every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 15 to 30 mcg/kg/dose immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg have been effective.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e640fa2-c778-4cda-8fb6-41b7a2b72227">Congenital hemophilia A or B with inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital hemophilia A or B with inhibitors:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes:</i> 90 mcg/kg/dose every 2 hours until hemostasis is achieved or until the treatment is judged ineffective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16990605','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16990605','lexi-content-ref-Manu.1'])">Ref</a></span>). The dose, interval, and duration of therapy may be adjusted based upon the severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds, dosing should be continued at 3- to 6-hour intervals post-hemostasis. The duration of any post-hemostatic dosing should be minimized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 90 mcg/kg/dose immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 48 hours, then every 2 to 6 hours until healed. For major surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 5 days, then every 4 hours or by continuous infusion at 50 mcg/kg/hour until healed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Secondary prophylaxis of bleeding events (off-label use):</i> 90 mcg/kg once daily. In a clinical trial, male patients with frequent bleeds (mean ≥4 bleeding events per month requiring hemostatic therapy) received prophylaxis for a duration of 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17723130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17723130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SevenFact:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Maximum dosage has not been established; cumulative daily dosages &gt;900 mcg/kg, which may be associated with a greater risk of thromboembolic complications, have not been studied.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to moderate bleeding (eg, </i>
<i>joint, superficial muscle, soft tissue and mucous membranes)</i>: 75 mcg/kg every 3 hours until hemostasis is achieved <b>OR</b> initial dose of 225 mcg/kg and if hemostasis is not achieved within 9 hours, administer 75 mcg/kg every 3 hours as needed to achieve hemostasis. If successful control of bleeding does not occur within 24 hours of initial administration, consider alternative treatments. Continue therapy to support healing and prevent recurrent hemorrhage after hemostasis to maintain the hemostatic plug.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe bleeding (eg, life- or limb-threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or GI)</i>: Initial: 225 mcg/kg, then 6 hours later (if needed) administer 75 mcg/kg every 2 hours until hemostasis is achieved; continue therapy to support healing and prevent recurrent hemorrhage.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9763a7a-dfcc-491c-9885-ebb564d91513">Glanzmann thrombasthenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glanzmann thrombasthenia: </b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bleeding episodes</i> (severe, refractory to platelet transfusions): 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perioperative management:</i> 90 mcg/kg/dose immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher doses (100 to 140 mcg/kg) may be used for surgical patients who have clinical refractoriness with or without platelet-specific antibodies compared to those with neither.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f919a38-e833-4926-93fb-34b760799a39">Intracranial hemorrhage associated with danaparoid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial hemorrhage associated with danaparoid (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing based on NovoSeven RT studies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 90 mcg/kg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67db7e51-6f5f-4bd8-bf85-011c956bb756">Intracranial hemorrhage associated with low molecular weight heparin</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial hemorrhage associated with low molecular weight heparin (if protamine is contraindicated) (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not for use in patients with intracranial hemorrhage receiving prophylactic low molecular weight heparin. Dosing based on NovoSeven RT studies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 90 mcg/kg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d0aba10-dcbb-4614-95e4-172518a59013">Refractory bleeding after cardiac surgery in nonhemophiliac patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Refractory bleeding after cardiac surgery in nonhemophiliac patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing not established; recommendations based on low-quality evidence (case series, observational studies using NovoSeven RT).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial range of ~11 to 22 mcg/kg/dose (median ~17 mcg/kg) has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996457','lexi-content-ref-16632803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996457','lexi-content-ref-16632803'])">Ref</a></span>); others have used a range of ~35 to 72 mcg/kg/dose (median ~49 mcg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18606914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18606914'])">Ref</a></span>). For persistent bleeding, 1 or 2 additional doses may be required in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21601468','lexi-content-ref-17996457','lexi-content-ref-18606914','lexi-content-ref-16632803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21601468','lexi-content-ref-17996457','lexi-content-ref-18606914','lexi-content-ref-16632803'])">Ref</a></span>). In patients with a left ventricular assist device, a single lower dose of 10 to 20 mcg/kg may be preferred to reduce thromboembolic events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19632574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19632574'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992024"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided the in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989314"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F169423"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (2%), thrombosis (≤4%; including internal jugular thrombosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum fibrinogen (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site, hematoma at injection site, infusion site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache (1%), intracranial hypertension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hemarthrosis (acute, postoperative: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, cerebral ischemia, cerebrovascular accident, deep vein thrombosis, localized phlebitis, occlusion of cerebral arteries, pulmonary embolism, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis, deep vein thrombophlebitis, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular disease, pain</p></div>
<div class="block coi drugH1Div" id="F169435"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">NovoSeven RT: There are no contraindications listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">SevenFact: Severe hypersensitivity to factor VIIa (recombinant)-jncw or any component of the formulation; known allergy to rabbits or rabbit proteins.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Known hypersensitivity to eptacog alfa (activated), any component of the formulation, or to mouse, hamster, or bovine protein.</p></div>
<div class="block war drugH1Div" id="F169420"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: If factor VIIa activity does not reach the expected level, prothrombin time is not corrected, or bleeding is uncontrolled (with recommended doses), suspect antibody formation and perform antibody analysis. Prothrombin time and factor VII coagulant activity should be measured before and after administration in patients with factor VII deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with use. Patients with known hypersensitivity to rabbit, mouse, hamster, or bovine proteins, or IgE-based hypersensitivity to casein may be at higher risk. If hypersensitivity reaction occurs, discontinue use and administer appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis.</b> All patients receiving factor VIIa should be monitored for signs and symptoms of activation of the coagulation system or thrombosis; thrombotic events may be increased in patients with history of congenital or acquired hemophilia receiving concomitant treatment with activated or nonactivated prothrombin complex or other hemostatic agents, older patients with acquired hemophilia receiving other hemostatic agents, or patients with a history of atherosclerotic or coronary artery disease, cerebrovascular disease, crush injury, septicemia, or thromboembolism. Decreased dosage or discontinuation is warranted with confirmed intravascular coagulation or presence of clinical thrombosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Reduced efficacy: A number of factors influence the efficacy of factor VIIa, including hypothermia, thrombocytopenia, acidosis, and the amount of blood products transfused prior to administration (Dunkley 2008).</p></div>
<div class="block foc drugH1Div" id="F169430"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sevenfact: Factor VIIa, recombinant-jncw 1 mg (1 ea); Factor VIIa, recombinant-jncw 5 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoSeven RT: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea); 8 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F169417"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323142"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (NovoSeven RT Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (0 Price provided is per microgram): $3.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (0 Price provided is per microgram): $3.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (0 Price provided is per microgram): $3.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (0 Price provided is per microgram): $3.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Sevenfact Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (0 Price provided is per microgram): $3.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (0 Price provided is per microgram): $3.07</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866858"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NiaStase RT: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block adip drugH1Div" id="F53566681"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Each mg of NovoSeven RT contains 0.4 mEq sodium and 0.01 mEq calcium.</p></div>
<div class="block admp drugH1Div" id="F52612792"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV administration only:</p>
<p style="text-indent:-2em;margin-left:2em;">NovoSeven RT: Use NS to flush line (if necessary) before and after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: Administer as a slow bolus over 2 to 5 minutes. Do not mix with other infusion solutions.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: May be infused as a continuous IV infusion for perioperative management of major bleeding in patients with congenital hemophilia A or B. Continuous infusions should be infused via an infusion pump.</p>
<p style="text-indent:-2em;margin-left:2em;">SevenFact: Intermittent IV: Administer over ≤2 minutes Do not mix with other infusion solutions.</p></div>
<div class="block adm drugH1Div" id="F169432"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Administer over 2 to 5 minutes (depending on the dose). Use NS to flush line (if necessary) before and after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: May be infused as a continuous IV infusion for perioperative management of major bleeding in patients with congenital hemophilia A or B. Continuous infusions should be infused via an infusion pump.</p>
<p style="text-indent:-2em;margin-left:2em;">SevenFact:</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Administer over ≤2 minutes.</p></div>
<div class="block sts drugH1Div" id="F169440"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">NovoSeven RT: Prior to reconstitution, store between 2°C to 25°C (36°F to 77°F); do not freeze. Protect from light. Reconstituted solutions may be stored at room temperature or under refrigeration but must be infused within 3 hours of reconstitution. Do not freeze reconstituted solutions. Do not store reconstituted solutions in syringes.</p>
<p style="text-indent:-2em;margin-left:2em;">SevenFact: Prior to reconstitution, store between 2°C to 30°C (36°F to 86°F); do not freeze. Protect from light. Reconstituted solutions should be stored at room temperature but may be stored between 2°C to 30°C (36°F to 86°F) for up to 4 hours. Do not freeze reconstituted solution or store in syringes.</p></div>
<div class="block usep drugH1Div" id="F53566845"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">NovoSeven RT: Treatment of bleeding episodes and perioperative management in patients with hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets (FDA approved in all ages); treatment of bleeding episodes and perioperative management in patients with acquired hemophilia (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">SevenFact: Treatment and control of bleeding episodes in patients with hemophilia A or B with inhibitors (FDA approved in ages ≥12 years and adults). <b>Note:</b> SevenFact is not indicated for the treatment of patients with congenital factor VII deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for secondary prophylaxis of bleeding events in male patients with hemophilia A or B with inhibitors and who have frequent bleeds requiring hemostatic therapy.</p></div>
<div class="block cyt drugH1Div" id="F13299309"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220313"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anti-inhibitor Coagulant Complex (Human): May enhance the thrombogenic effect of Factor VIIa (Recombinant). Management: Consider avoiding concomitant use of factor VIIa (recombinant) and activated prothrombin concentrates, such as anti-inhibitor coagulant complex (human), due to an increased risk of developing thrombotic events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Concizumab: Factor VIIa (Recombinant) may enhance the thrombogenic effect of Concizumab.  Management: Discontinue treatment with recombinant factor VIIa (rFVIIa) at least 12 hours before starting concizumab. If rFVIIa is required as a bypassing agent in a patient receiving concizumab prophylaxis, use the lowest possible effective rFVIIa dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor XIII A-Subunit (Recombinant): May enhance the thrombogenic effect of Factor VIIa (Recombinant).<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F169436"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F2181984"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant patients with inherited bleeding disorders, including factor VII deficiency and Glanzmann’s thrombasthenia, may have an increased risk of bleeding following abortion, antenatal procedures, delivery, and miscarriage; close surveillance is recommended. Patients with factor VII deficiency and severe or abnormal bleeding should be treated with recombinant factor VIIa. Patients with Glanzmann’s thrombasthenia and a history of bleeding can be treated prophylactically with recombinant factor VIIa at delivery (RCOG [Pavord 2017).</p></div>
<div class="block mopp drugH1Div" id="F53566846"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for evidence of hemostasis and thrombosis (including laboratory confirmation of intravascular coagulation, if appropriate). Although the prothrombin time (PT)/INR, aPTT, and factor VII clotting activity have shown no direct correlation with achieving clinical hemostasis, these parameters may be useful as adjunct tests to evaluate efficacy and guide dose or interval adjustments. In factor VII-deficient patients, monitor PT and factor VII clotting activity before and after administration. Monitor for factor VII antibodies, if the factor VIIa activity fails to reach the expected level, if PT is not corrected, or if bleeding is not controlled after treatment with recommended doses.</p></div>
<div class="block pha drugH1Div" id="F169419"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Recombinant factor VIIa, a vitamin K-dependent glycoprotein, promotes hemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor and may activate coagulation factor X to Xa and factor IX to IXa. When complexed with other factors, coagulation factor Xa converts prothrombin to thrombin, a key step in the formation of a fibrin-platelet hemostatic plug.</p></div>
<div class="block phk drugH1Div" id="F169434"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hemophilia:</p>
<p style="text-indent:-2em;margin-left:4em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">NovoSeven RT: Hemophilia A with inhibitors:</p>
<p style="text-indent:-2em;margin-left:8em;">Children:</p>
<p style="text-indent:-2em;margin-left:10em;">≤5 years: 145 ± 1 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 12 years: 149 ± 22 mL/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 130 ± 37 mL/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">SevenFact: 11.9 to 19.9 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Half-life, terminal:</p>
<p style="text-indent:-2em;margin-left:6em;">NovoSeven RT: Hemophilia A with inhibitors:</p>
<p style="text-indent:-2em;margin-left:8em;">Children:</p>
<p style="text-indent:-2em;margin-left:10em;">≤5 years: 1.9 ± 0.6 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 12 years: 3 ± 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 3.2 ± 0.3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">SevenFact: 1.4 to 1.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Excretion: Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;">NovoSeven RT: Hemophilia A with inhibitors:</p>
<p style="text-indent:-2em;margin-left:8em;">Children:</p>
<p style="text-indent:-2em;margin-left:10em;">≤5 years: 61 ± 9 mL/hour/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 12 years: 52 ± 12 mL/hour/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: 43 ± 15 mL/hour/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">SevenFact: 5.8 to 8 L/hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Factor VII deficiency: NovoSeven RT:</p>
<p style="text-indent:-2em;margin-left:4em;">Distribution: V<sub>ss</sub>: 230 ± 70 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Half-life, terminal: 2.62 ± 0.63 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Excretion: Clearance: 67.7 ± 17.9 mL/kg/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F169437"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven mixpro | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Novoseven rt</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Novoseven rt</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Recofact vii</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Novoseven rt</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Novoseven rt</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Arioseven | Coagil vii</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aryoseven | Novoseven</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Novoseven | Novoseven rt</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Novoseven</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16990605">
<a name="16990605"></a>Astermark J, Donfield SM, DiMichele DM, et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. <i>Blood</i>. 2007;109(2):546-551. doi:10.1182/blood-2006-04-017988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/16990605/pubmed" id="16990605" target="_blank">16990605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19632574">
<a name="19632574"></a>Bruckner BA, DiBardino DJ, Ning Q, et al, "High Incidence of Thromboembolic Events in Left Ventricular Assist Device Patients Treated With Recombinant Activated Factor VII," <i>J Heart Lung Transplant</i>, 2009, 28(8):785-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/19632574/pubmed" id="19632574" target="_blank">19632574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21601468">
<a name="21601468"></a>Chapman AJ, Blount AL, Davis AT, et al, "Recombinant Factor VIIa (NovoSeven RT) Use in High Risk Cardiac Surgery," <i>Eur J Cardiothorac Surg</i>, 2011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/21601468/pubmed" id="21601468" target="_blank">21601468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dunkley.1">
<a name="Dunkley.1"></a>Dunkley S, Phillips L, McCall P, et al. Recombinant activated factor VII in cardiac surgery: Experience from the Australian and New Zealand Haemostasis Registry. <i>Ann Thorac Surg</i>. 2008;85:836-844.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353044">
<a name="21353044"></a>Ferraris VA, Brown JR Despotis GJ, et al, "2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines," <i>Ann Thorac Surg</i>, 2011, 91(3):944-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/21353044/pubmed" id="21353044" target="_blank">21353044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15595332">
<a name="15595332"></a>Freeman WD, Brott TG, Barrett KM, et al, “Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial Hemorrhage,” <i>Mayo Clin Proc</i>, 2004, 79(12):1495-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/15595332/pubmed" id="15595332" target="_blank">15595332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17996457">
<a name="17996457"></a>Gelsomino S, Lorusso R, Romagnoli S, et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. <i>Eur J Cardiothorac Surg</i>. 2008;33(1):64-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/17996457/pubmed" id="17996457" target="_blank">17996457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617125">
<a name="18617125"></a>Ilyas C, Beyer GM, Dutton RP, et al, “Recombinant Factor VIIa for Warfarin-Associated Intracranial Bleeding,” <i>J Clin Anesth</i>, 2008, 20(4):276-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/18617125/pubmed" id="18617125" target="_blank">18617125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606914">
<a name="18606914"></a>Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. <i>Circulation.</i> 2008;118(4):331-338. doi: 10.1161/CIRCULATIONAHA.108.764308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/18606914/pubmed" id="18606914" target="_blank">18606914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17723130">
<a name="17723130"></a>Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. <i>J Thromb Haemost</i>. 2007;5(9):1904-1913.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/17723130/pubmed" id="17723130" target="_blank">17723130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18480205">
<a name="18480205"></a>Mayer SA, Brun NC, Begtrup K, et al, “Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,” <i>N Engl J Med</i>, 2008, 358(20):2127-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/18480205/pubmed" id="18480205" target="_blank">18480205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15728810">
<a name="15728810"></a>Mayer SA, Brun NC, Begtrup K, et al, “Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,” <i>N Engl J Med</i>, 2005, 352(8):777-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/15728810/pubmed" id="15728810" target="_blank">15728810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27913543">
<a name="27913543"></a>Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. <i>Hematology Am Soc Hematol Educ Program</i>. 2016;2016(1):657-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/27913543/pubmed" id="27913543" target="_blank">27913543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15693982">
<a name="15693982"></a>Mohr AM, Holcomb JB, Dutton RP, et al, “Recombinant Activated Factor VIIa and Hemostasis in Critical Care: A Focus on Trauma,” <i>Crit Care</i>, 2005, 9 (Suppl 5):37-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/15693982/pubmed" id="15693982" target="_blank">15693982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NovoNordisk.1">
<a name="NovoNordisk.1"></a>NiaStase RT (factor VIIa) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NovoNordisk.2">
<a name="NovoNordisk.2"></a>NovoSeven RT (factor VIIa) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16632803">
<a name="16632803"></a>Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. <i>Anesth Analg</i>. 2006;102(5):1320-1326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/16632803/pubmed" id="16632803" target="_blank">16632803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SevenFact.1">
<a name="SevenFact.1"></a>SevenFact (factor VIIa [recombinant]-jncw) [prescribing information]. Louisville, KY: HEMA Biologics; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12916 Version 181.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
